Abscint
ActiveSummary
Abscint has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5.6m and a net result of €363,834. Equity is growing by ~76.5% per year across the filed fiscal years. Its solvency ranks better than 79% of 642 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability75▲+75
Solvency100=
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €500,000 at 30 days acceptable
Liquidity ample (current ratio 3.89 against 3.54 in 2024; short-term debt: 12.6% and cash: 40.6% of total assets), and 18.9% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Human health activities (NACE 86)
about 87% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
81.1%
Return on assets
5.3%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-07-2026, 25 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
25 d early
2024
42 d early
2023
44 d early
2022
35 d early
2021
30 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 5 accounts on average 35 days before the deadline; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
28-09-2026 today31-12-2026 close31-07-2027 deadline
History
Abscint was incorporated on 6 July 2020 as a Public limited company.1 In 2026 the capital was increased by EUR 177,180 to EUR 7.4 million.2 The board currently has 2 members; Punam HOPE has served longest, since 2026.3 Total assets rose from EUR 507,291 in 2021 to EUR 6.8 million in 2025 and headcount from 1.3 to 2.7 full-time equivalents.4
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
In the rankings
#10 company by equity in Liège, Health and social work sector
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€363,834
2024 · -€1.3m
Working capital
€2.5m▲ 47.8%
2024 · €1.7m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result-€237,885--€463,511▼ 94.8%-€1.8m▼ 285%-€1.8m▲ 1.5%€247,495
Net result-€237,892below the sector's middle half--€463,591below the sector's middle half▼ 94.9%-€1.0mbelow the sector's middle half▼ 118%-€1.3mbelow the sector's middle half▼ 32.4%€363,834above the sector's middle half
Equity€422,034above the sector's middle half-€1.3mabove the sector's middle half▲ 207%€4.5mabove the sector's middle half▲ 246%€3.5mabove the sector's middle half▼ 22.6%€5.6mabove the sector's middle half▲ 60.3%
Total assets€507,291within the sector's middle half-€1.5mabove the sector's middle half▲ 186%€4.7mabove the sector's middle half▲ 227%€4.3mabove the sector's middle half▼ 9.8%€6.8mabove the sector's middle half▲ 60.3%
Debt€85,258-€154,155▲ 80.8%€257,515▲ 67.0%€804,417▲ 212%€1.3m▲ 60.6%
Working capital€315,599-€911,764▲ 189%€3.2m▲ 255%€1.7m▼ 47.9%€2.5m▲ 47.8%
Solvency83.2%above the sector's middle half-89.4%above the sector's middle half▲ 6.2pp94.6%above the sector's middle half▲ 5.2pp81.2%above the sector's middle half▼ 13.4pp81.1%above the sector's middle half=
Staff (FTE)1.3-2▲ 53.8%2=3within the sector's middle half▲ 50.0%2.7within the sector's middle half▼ 10.0%
above
within
below
the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings.
Result per fiscal year
Operating resultNet result
The operating result returns to profit in 2025: €247,495 after a loss of €1.8m in 2024, the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €6.8m
Fixed assets
€3.5m ▲ 81.7%
Current assets
€3.4m ▲ 42.8%
Equity and liabilities €6.8m
Equity
€5.6m ▲ 60.3%
Debt
€1.3m ▲ 60.6%
Debt's share of the balance-sheet total stays at 18.9%.
Key figures and ratios
EBITDA
€541,184▲
2024 · -€1.0m
Cash flow
€657,522▲
2024 · -€618,870
Current ratio
3.89▲
2024 · 3.54
Debt to equity
0.23▲
2024 · 0.23
ROE
6.5%▲
2024 · -38.7%
ROA
5.3%▲
2024 · -31.4%
Interest coverage
45.41▲
2024 · -209.68
Debt ≤ 1 year
€862,811▲
2024 · €663,962
Debt > 1 year
€428,699▲
2024 · €140,455
Income taxes
-€60,834▼
2024 · -€51,489
Staff costs
€327,470▼
2024 · €376,742
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 26,964 companies that looked in July 2024 the way this one looks now, 1.5% went bankrupt within 24 months and 95% are still going.
- Micro
- 5 to 10 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
1.5%
went bankrupt
3.4%
stopped otherwise
95%
still going
A further 0.3% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.6% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 26,964 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | €1.3m | - |
| Remuneration, social security and pensions62 | €102,244 | €183,941 | €230,738 | €376,742 | €327,470 | ▼ 13.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €9,248 | €29,843 | €1.2m | €721,576 | €293,689 | ▼ 59.3% |
| Other operating charges640/8 | €695 | €0 | €782 | €0 | €2,196 | - |
| Non-recurring operating charges66A | - | - | €62,498 | €0 | - | - |
| Gross operating margin9900 | -€125,698 | -€249,727 | -€328,168 | -€660,224 | €870,849 | ▲ 232% |
| Operating profit (loss)9901 | -€237,885 | -€463,511 | -€1.8m | -€1.8m | €247,495 | ▲ 114% |
| Financial income75/76B | €5 | €9 | €748,739 | €371,553 | €67,422 | ▼ 81.9% |
| Recurring financial income75 | €5 | €9 | €748,739 | €371,553 | €67,422 | ▼ 81.9% |
| Financial charges65/66B | €11 | €89 | €3,585 | €4,946 | €11,918 | ▲ 141% |
| Recurring financial charges65 | €11 | €89 | €3,585 | €4,946 | €11,918 | ▲ 141% |
| Profit (loss) for the period before taxes9903 | -€237,892 | -€463,591 | -€1.0m | -€1.4m | €302,999 | ▲ 122% |
| Income taxes67/77 | - | - | -€27,947 | -€51,489 | -€60,834 | ▼ 18.1% |
| Profit (loss) for the period9904 | -€237,892 | -€463,591 | -€1.0m | -€1.3m | €363,834 | ▲ 127% |
| Profit (loss) for the period to be appropriated9905 | -€237,892 | -€463,591 | -€1.0m | -€1.3m | €363,834 | ▲ 127% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €507,291 | €1.5m | €4.7m | €4.3m | €6.8m | ▲ 60.3% |
| Formation expenses20 | - | - | €4,950 | €0 | €2,169 | - |
| Fixed assets21/28 | €106,434 | €384,188 | €1.2m | €1.9m | €3.5m | ▲ 81.7% |
| Intangible fixed assets21 | €105,112 | €378,800 | €1.2m | €1.9m | €3.5m | ▲ 82.0% |
| Tangible fixed assets22/27 | €1,322 | €5,388 | €6,599 | €3,964 | €1,563 | ▼ 60.6% |
| Plant, machinery and equipment23 | - | €4,613 | €3,494 | €2,375 | €1,255 | ▼ 47.1% |
| Furniture and vehicles24 | €1,322 | €775 | €3,105 | €1,589 | €308 | ▼ 80.6% |
| Financial fixed assets28 | - | - | €1,260 | €1,260 | €1,260 | = |
| Current assets29/58 | €400,857 | €1.1m | €3.5m | €2.3m | €3.4m | ▲ 42.8% |
| Stocks and contracts in progress3 | €1,279 | €0 | - | - | - | - |
| Stocks30/36 | €1,279 | €0 | - | - | - | - |
| Amounts receivable within one year40/41 | €34,481 | €78,300 | €499,548 | €191,537 | €570,670 | ▲ 198% |
| Trade receivables40 | - | - | - | €2,678 | €3,431 | ▲ 28.1% |
| Other amounts receivable41 | €34,481 | €78,300 | €499,548 | €188,859 | €567,239 | ▲ 200% |
| Cash at bank and in hand54/58 | €364,385 | €985,908 | €3.0m | €2.1m | €2.8m | ▲ 29.4% |
| Deferred charges and accrued income490/1 | €712 | €1,712 | €1,602 | €8,685 | €2,121 | ▼ 75.6% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €507,291 | €1.5m | €4.7m | €4.3m | €6.8m | ▲ 60.3% |
| Equity10/15 | €422,034 | €1.3m | €4.5m | €3.5m | €5.6m | ▲ 60.3% |
| Contributions10/11 | €659,925 | €2.0m | €6.2m | €6.2m | €7.2m | ▲ 17.0% |
| Capital10 | €659,925 | €2.0m | €6.2m | €6.2m | €7.2m | ▲ 17.0% |
| Issued capital100 | €659,925 | €2.0m | €6.2m | €6.2m | €7.2m | ▲ 17.0% |
| Profit (loss) carried forward14 | -€237,892 | -€701,483 | -€1.7m | -€3.1m | -€2.7m | ▲ 11.9% |
| Investment grants15 | - | - | - | €327,729 | €1.0m | ▲ 205% |
| Amounts payable17/49 | €85,258 | €154,155 | €257,515 | €804,417 | €1.3m | ▲ 60.6% |
| Amounts payable after more than one year17 | - | - | - | €140,455 | €428,699 | ▲ 205% |
| Financial debts170/4 | - | - | - | €140,455 | €428,699 | ▲ 205% |
| Amounts payable within one year42/48 | €85,258 | €154,155 | €257,515 | €663,962 | €862,811 | ▲ 29.9% |
| Current portion of amounts payable after more than one year42 | - | - | - | - | €350,000 | - |
| Trade debts44 | €71,624 | €130,182 | €227,230 | €264,736 | €483,292 | ▲ 82.6% |
| Suppliers440/4 | €71,624 | €130,182 | €227,230 | €264,736 | €483,292 | ▲ 82.6% |
| Taxes, remuneration and social security45 | €13,634 | €23,147 | €29,459 | €42,692 | €28,693 | ▼ 32.8% |
| Taxes450/3 | €661 | €4 | €0 | - | - | - |
| Remuneration and social security454/9 | €12,973 | €23,143 | €29,459 | €42,692 | €28,693 | ▼ 32.8% |
| Other amounts payable47/48 | - | €826 | €826 | €356,534 | €826 | ▼ 99.8% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€237,892 | -€463,591 | -€1.0m | -€1.3m | €363,834 | ▲ 127% |
| + Depreciation and write-downs630 | €9,248 | €29,843 | €1.2m | €721,576 | €293,689 | ▼ 59.3% |
| Operating cash flow (approximation) | -€228,643 | -€433,749 | €150,915 | -€618,870 | €657,522 | ▲ 206% |
| Investment in fixed assets (approximation) | - | -€307,597 | -€2.0m | -€1.4m | -€1.9m | ▼ 32.9% |
| Change in cash | - | €621,523 | €2.0m | -€841,332 | €631,844 | ▲ 175% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
21-09
State Gazette act
Resignations: CBD Consulting, Qbic Venture Partners II and 4 othersAppointments: Xavier, Anne, Jean-Louis DEFOURT (director) and Punam HOPE (director) · Director discharge · Declaration21 facts ▸
State Gazette act
Resignations: CBD Consulting, Qbic Venture Partners II and 4 others
Appointments: Xavier, Anne, Jean-Louis DEFOURT (director) and Punam HOPE (director) · Director discharge · Declaration21 facts ▸
- General meeting, 07-08-2026
- Director resignation, CBD Consulting (director)
- Director resignation, Qbic Venture Partners II (director)
- Director resignation, NOSHAQ PARTNERS (director)
- Director resignation, Didier Allaer (director)
- Director resignation, Jacobus Boonen (director)
- Director resignation, Koen Dewaele (director)
- Director resignation, CBD Consulting (managing director)
- Director discharge, CBD Consulting (director)
- Director discharge, Qbic Venture Partners II (director)
- Director discharge, NOSHAQ PARTNERS (director)
- Director discharge, Didier Allaer (director)
- +9 further facts in this act
25-08
State Gazette act
Capital & shares · Statutes amendmentFinancial instrument · Capital increase · Bank account13 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Financial instrument · Capital increase · Bank account13 facts ▸
- Other statement, comparution par mandataire spécial, mandataire spécial
- Other statement, 90600, relevé des droits de souscription
- Financial instrument, Plan d’Options sur Actions 2021(I), actions ordinaires
- Financial instrument, Plan d’Options sur Actions 2021(II), actions ordinaires
- Financial instrument, Plan d’Options sur Actions 2022(I), actions ordinaires
- Financial instrument, Plan d’Options sur Actions 2023(I), actions ordinaires
- Other statement, remise du relevé au notaire, relevé des droits de souscription
- Capital increase, €177.180
- Bank account, compte spécial au nom de la Société
- Other statement, 30-07-2026
- Share issue, actions ordinaires, 90600
- Capital, €7.425.517,1
- +1 further facts in this act
06-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Back to profitnet €363,834
Net result €363,834 after 4 loss-making years.
31-12
Financial
Equity above €5mEq €5.6m ▲60.3%
Equity rises from €3.5m to €5.6m.
19-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Weakest financial yearnet -€1.3m
Net result drops to -€1.3m, the lowest in the series; recovery starts the following year.
17-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Equity above €2mEq €4.5m ▲246%
Equity rises from €1.3m to €4.5m.
26-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Equity above €1mEq €1.3m ▲207%
Equity rises from €422,034 to €1.3m.
01-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
2 of 12 acts read
About the unread acts
Of the 12 Belgian State Gazette acts we know for this company, 2 have been read. The other 10 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 directors, last change in 2026
Punam HOPE
CurrentDirector · since 07-08-2026
Xavier, Anne, Jean-Louis DEFOURT
CurrentDirector · since 07-08-2026
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
10 of this company's 12 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Liège · 2 establishment units since 2020
Ground area
2.1 ha
Building footprint
1,024 m²
Volume, LiDAR
13,845 m³
2 parcels, Brussels, Wallonia · tallest building 22.9 m, ±5 floors. Linked by address, not a title deed.
43
companies at this address
See who is registered here
2 establishment units
Abscint
since 20202.307.844.883
Abscint
since 20222.357.421.088
2 parcels
Wallonia
1
(50%)
Brussels
1
(50%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62042B0366/00B003 | Wallonia | 1.9 ha | - | - |
| 21307F0170/00A003 | Brussels | 2,276 m² | 1 · 1,024 m² | 22.9 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
8 people since 2026, 2 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Punam HOPE |
|
| Xavier, Anne, Jean-Louis DEFOURT |
|
| CBD Consulting |
|
| Didier Allaer |
|
| Jacobus Boonen |
|
| Koen Dewaele |
|
| NOSHAQ PARTNERS |
|
| Qbic Venture Partners II |
|
Structure & network
Owners and holdings
3 ownersOwners 3
-
20.5%
-
14.21%
-
13.93%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
2 current directorsThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Capital and shareholders
Capital over the years
- 25-08-2026 Capital increase of 177,180 EUR · to 7,425,517.10 EUR · 90,600 new shares · in cash
Similar companies · same sector, comparable size
Dr. Tania Bril, klinisch bioloog
BE 0632.583.025
Waasmunster · Eq €5,323,382
NAMSA BELGIUM
BE 0552.767.762
Diest · Eq €5,286,277
LABORATOIRE STE-ANNE ET ST-JEAN
BE 0419.061.477
Brussel · Eq €4,891,737
CENTRUM VOOR MEDISCHE ANALYSE
BE 0437.882.546
Herentals · Eq €6,472,612
Association interhospitalière de la Région de Charleroi
BE 0440.543.118
Charleroi · Eq €6,567,555
Of 699 companies in sector 86910 we hold annual accounts for 522. 233 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded06-07-2020
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
86910Medical imaging and medical laboratories
E-invoicing
Reachable via Peppol
Peppol ID
0208:0749828410
Registered
19-01-2026
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.